NIH Research Festival
Recent reports have suggested that leukemic microenvironments (ME) play a key role to support leukemogenesis through interacting with leukemia stem cells (LSC). In other way of thinking, the cell components of leukemic or pre-leukemic ME may convert to hematopoietic malignancy initiating cells. To test the hypothesis, we established two cell lines from the bone marrow (BM) cells of NUP98-HOXD13 (NHD13) mouse model of myelodysplastic syndrome (MDS). These cell lines can change their morphology from fibroblast-like to hematopoietic cell and vice versa. Moreover, these cells convert CD45 antigen reversibly. Interestingly, these cells have retained malignant potential, when those were transplanted to irradiated healthy recipients. Taken together, these findings suggest that malignant cells can cycle between stromal and hematopoietic cells, and support the hypothesis that non-hematopoietic BM cells, the cell components of ME, may be an important part of the malignant clone in patients with MDS and AML.
Scientific Focus Area: Cancer Biology
This page was last updated on Friday, March 26, 2021